Alendronato sódico en pacientes osteoporósicos con fractura de cadera. (Chino)

Qiu GX, Wu ZH, Shen JX, Luo XZ, Tang H, Wang YP, Weng XS, Yang XY, Lin J, Jin J, Zhao H, Tian Y, Zhang JG.
Department of Orthopeadic, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing 100730, China.

OBJECTIVE: To assess efficacy and safety of alendronate sodium treatment in osteoporosis patients with hip fracture.

METHODS: One year randomized, double-blind clinical trial was carried out in 77 osteoporosis patients with hip fracture. The bone mineral density (BMD) in lumbar spine (L(2 - 4)), femoral neck (Neck), Wards triangle (Wards) and great trochanter (Troch) was measured by dual energy x-ray absorptiometer (DEXA).

RESULTS: In our study, alendronate sodium induced marked increases in BMD of the L(2 - 4) (7.0% +/- 13.0%), Neck (7.3% +/- 11.1%), Wards (4.6% +/- 5.9%), Troch (4.5% +/- 3.2%) (mean +/- s) versus decreases of 2.0% +/- 4.5%, -0.9% +/- 6.9%, 3.6% +/- 4.9% and 1.14% +/- 6.0% with placebo (P < 0.05). Blood Ca, P, ALP, BGP and Urine Pyd/C were no significant difference between before and after therapy. There were usually mild and transient side-effect, such as gastrointestinal symptoms.

CONCLUSION: Alendronate is an efficacy and safety drug in treatment of osteoporosis.